INTRODUCTION
Schizophre nia was classified as a synd ro me almost 100 years ago, a nd whi le th is illn ess wa s well cha rac te rized by Kraepelin, Bleu ler a nd o t he rs, adeq uat e t rea t m en t for t his disorder did not becom e avai lable until th e 1950 's. Earl ier t rea t m e nts included hydrotherapy, insulin shock th erapy, e lec t roconvulsive t herapy, and front a l lob otomy. However in 1952 , with th e int roducti on of chlo rp rom a zine , t he treatm e nt approach to schizo p hre nia was ra dica lly cha nged . Fo r th e firs t ti me, a med ica tion was available that was effec t ive in co n t rolling psych oti c sym p to ms in a large nu m be r of patien ts . Patients improved e noug h to benefit from other th e rapi es, including support ive and g ro up psychotherapy, recr eational th erapy a nd occ upa tional th erapy. These mod alities could now be used effec t ively to provide lon g-t e r m psych oso cial rehabilitation in o rde r to improve th e quality of life of pati ents with schizophreni a .
The well kn own pharmacologic effec t of dopam in e (DA) block ad e by chlorpromazin e lead to t he dopamine hypothesis of sch izophreni a whi ch truly revolutioni zed our Sco tt A. West , M.D. is a Fellow in th e Biological Psychi at ry Pro gra m a t th e U niversi ty of Ci ncinnat i Co lleg e of Med icine. 8 conce p t ualiza t io n of this illn ess, a nd served as a maj or impetus to int ensely scru tinize th e neuroch emistry of th e disorder ( 1,2). Subse q ue nt to t he introduction of chlorprom azine, num erous ot he r dopami ne blocking age nts, ini tiall y ca lled "neu rol eptics" becau se they have th e inherent ris k of pr oducin g ex t ra pyra m ida l neurological side effec ts, have becom e availa ble for th e treatm ent of schizop hr enia. The introduct ion of cloza pine beg an a n ew e ra in th e ph arm acologic manage m e nt of schi zophrenia . C loza pine beca m e th e first true "atypica l" a n tipsyc ho tic m ed ication avai lable for clinica l use. Antipsychotics classified as "atypica l" gene ra lly include th e following characte ristics : th ey (I) do not ca use ca tale psy in a nimal models, (2) ca use minim al or no ex t rapyra m idal sym ptoms (EPS) in hu m a ns, (3) have little effec t on plasm a pr olactin conce n tra t io ns (t ypi cal a n ti psyc hot ics increase plasma prolactin) , (4) have greater 5-H T 2 receptor blo ck ad e th an ty pica l a n t ipsyc hot ic medi cations, (5 ) tend to have more D, recept or blo ckad e th an typi cal a n t ipsychot ics. T hus, atypical a n t ipsycho tics suc h as clo zapine have minimal or no liab ilit y for producing movem ent di sorders, a tremendous adva n tage co ns idering a pproximately 15-20 percent of all patients on lon g-t erm a n tipsyc ho t ic drugs d evelop tardive dys kin esia, and a not her I percent devel op ta rdi ve dystonia (3) (4) (5) .
Th e recent explosion of research in neuroscience and th e effec t ive ness of th e a ty pica l a n tipsyc hot ics has led t o t he investigat ion of neu rot ra nsm itt e r syst ems o t her than dopamin e as import ant ph a rm acological strategies for th e treatm ent of schizophrenia. Other sys te ms unde r in vest igat ion t hat have been implicated in th e pathoph ysiol ogy of sch izo p hre nia incl ude seroto nin (5-HT) , o -opioid , neurot en sin (NT), a nd N-m ethyl-D-asparta t e (N M DA) .
This pap er will review th e ph arm acological strategies us ed in th e developm en t of new an ti psyc ho tic drugs, as th e pat ho phys iology of schizophrenia becomes furth er eluc idate d . N umerous m edi ca tion s, incl uding many atypica l antipsychotic drugs, are a t va rious stages in clinical t ri al s, a nd some will becom e avai lable for clini cal use in th e near futur e. Sinc e clozapine is curren tly th e only atypical antipsych otic dru g ava ila ble for use, it will be add res se d in d et ail.
Pharmacological S trategies
The dopaminergic syste m has t ra d itionally bee n th e primary focus of m an y inves t igatio nal dru gs du e to th e efficacy of D 2 antagonists in controlling th e positive sym p to ms (eg. hallucin ations, d elu sion s) of schizophrenia (1,2) . D r ugs that a re se lec tive D 2 an t agonist s have proven to be clinicall y useful , yet the pot ential for th e development of EP S and tardive dysk in esia remains rela tively hig h, whi ch is a m ajor di sadvant a ge . Drugs in this class includ e th e benzamides su lp irid e (the protot yp e), racloprid e a nd re mo xipride; st ud ies have demon stra t ed t hat t he la tt e r two m edi cati on s a re efficacious and well -t olerat ed , a nd th ey may receive FDA approval soo n (6).
T ergu rid e is a partial D 2 agoni st that may be effective in alleviating both positive a nd negative sym p to ms (eg. blunted affect , socia l isola ti on) of schizophrenia (7) . Part ial D 2 agonists a re ca pable of up or down regulati ng different dopaminergic pathways by in cr easing or d ecr eas in g ne uro t ra ns miss ion in hyp o-o r hyp er-functioning pathways, resp ectively. The hypoth esis th at th e re is a reducti on of syna pt ic DA in th e front al cor te x whi ch results in th e nega t ive symptoms and an incr ease in syna pt ic DA in th e m esolimbic syst em resulting in posit ive symptoms has led t o th e use of partial ag onists to modulat e th ese circ u its.
Th e identification of multiple subtypes of DA receptors has led to th e developm ent of other hypotheses in addition to D z dysr egul ation. Pr eferent ial D , antagonism (D ) > D z ) seems to play a n import ant rol e in th e treatm ent of many schizoph renic pati ents (7, 8) . Se ve ra l drugs have recently been identified that are mu ch mor e se lec tive for D ) recept ors, without strong cho line rg ic, seroto ne rgic, and noradren crgic activit y (7). Pr eferential D ) antagonist s appea r to have very littl e pot ential for producin g EPS , whi ch may imply th at th e ratio of D,:D z blockad e is an important fac to r in th e development of EPS.
There a re seve ra l se ro to nin-based s t ra tegies, a nd 5-H T z antagonist s see m to be particul a rly pr o mi sin g (6, 7, 9) . It has been postulat ed th a t bloc ka de of 5-HT z receptors is th e m echanism responsibl e for th e success of cloza pin e in improving th e neg ative sym p to ms of schizophrenia. Other drugs wit h sig nifica n t 5-H T z blocka de include Auperlapine, sertindole, ola nzapi ne , a nd risp eridon e, which has recent ly been filed with th e FDA a nd is awa it ing a pproval. Addit ionally, 5-HT 3 an tagonists a nd 5-HT) a agonists a re a lso und er inves tiga t io n; however, th e ant ipsychotic efficacy of th ese ag ents is not well es ta blishe d.
Th e rol e of o-opioid receptors in the pathophysiolo gy of sc hizo phre nia is also under inv estigation (7, 10) . This a pproach is based o n evide nce th a t typ ica l a n ti psycho t ic drugs, suc h as haloperidol, have a n affinity to th e rr-opioid receptor, a nd it has been postul at ed th at this m ay co nt ribu te t o th e a nt ipsychotic efficac y of th ese m edi cation s. It has a lso been d emonstrat ed th at rem oxiprid e has an affinity to th e rr-opioid receptor. Th e o-opioid a n tagonist rimca zole ha s been di sappoint ing howeve r, du e to bo th it s lack of efficacy a nd an unfavorabl e side effec t profile, including a rel atively high incid en ce of se izures (7) .
Ne urote ns in (1\ '1'), a n e ndoge no us trid ecapeptid e, possesses many ph armacologica l pr op erti es in com mo n with a ty pica l a nt ipsyc ho tics (II ). It has bee n d e monst ra ted th at both typi cal a nd at ypi cal a nt ipsycho t ic dru gs incr ease NT co nce n t rat ions in th e nucl eu s acc um be ns, a nd typi cal a n t ipsyc ho tics in crease NT conce n trations in th e ca uda te nucl eu s as well (12) (13) (14) . Th e d evel op m ent of l\TT agonists will allow its rol e in th e pathophysiology of schizo phre nia to be furt her elucid a t ed .
NMDA agonism m ay provide ye t a no t he r p romisin g ap proach to th e dev elopm ent of a typica l antipsych oti c drugs. Th e ph en cyclidine (PC P) /NMDA mod el of sc hizop hre nia hypoth esiz es th at th ere is a rel ative d ecr ease in glu tama te rg ic neurotransmission du e to inhibition of th e NMDA typ e of glu ta mate recept or (15, 16) . This mod el was origina lly pr op osed a fte r num erou s pat ie n ts wit h PCP intoxication present ed with a clini cal picture indistingui sh abl e fro m sc hizo phre nia , including th e pr esen ce of both positive and negative sym pto ms (16) . Therefore, NM DA agon ists ca pa ble of incr easin g glu tama te rg ic/NM DA neurot ran smi ssion m ay prove to be ve ry useful. M edi ca tions developed thus far ha ve been int olerabl e for pa t ie n ts, a nd cu rre n t ly th ere a re no drugs in clinical use. Howeve r, t he addit ion of t he amino ac id glycine , a co-agonist a t t he NM DA rece ptor co m plex , to typical antipsychot ic m edi ca ti o ns has proven to be a useful adj uva n t for som e pa t ie n ts ( 17, 18) .
Clozapi ne C lozapine was developed over thirty yea rs ago, a nd has be en us ed ext en sively in Europe since th e 1960 's. Shortly a fte r th e st udy publish ed by Shopsin e t a l ( 1979) , clozapine was banned fr om furth er inves tiga tio n in th e Unit ed St at es du e to a numbe r of fa tal cas es of ag ranulocytosis associa ted wit h it s use ( 19) . Howeve r, cloza pin e was reintroduced int o the U ni t ed Stat es sev e ra l yea rs lat er, a nd th e hall m a rk st udy by Ka ne e t a l ( 1988), d e mon stra ting its efficac y in treatm entres ista nt schizoph re nic patients, led to it s eve n t ua l a pproval by th e FDA in 1990. The a p proval had th e st ipu la t ion th at weekly white blood counts (W BC s) woul d be monitored in patients in ord er to d et ect th e rare occu ra nce of agranu locyt osis (20) . Clozapine is cur re n t ly indica te d for use in patien ts wh o a re t reatment-resist ant , loosely d efin ed as those who have fail ed trial s of seve ra l di fferen t typical an tipsych oti c dru gs, or in patients wh o are un abl e to tolerat e typi cal ant ipsycho tic dru gs du e to seve re sid e effects, including tardive dyskinesia.
Pharmacology
C lozapine is a dib e nzod ia zepi ne th at is chem ica lly relat ed to th e typical a nt ipsycho t ic loxapin e (2 1). C loza pin e is not a selective DA an tagonist ; in fact it has g rea t er affinity for cho line rg ic (m uscarinic), serotonergic, no rad re ne rgic (a ) and ( 2), a nd histaminergic (H) ) receptors th an for dopamine rgic recept or s (22) (23) (24) (25) . Whi le th e precise m ech anism of ac tio n is unknown , m an y a u t hors have pos t ula ted tha t th e 5-HT 2 a n tagonism of clozapin e acco un ts (a t least in part ) for its efficacy, es pec ia lly wit h regard to im prove me n ts in nega tive symptoms common ly obs erved in pa tients (6) . Block ad e of th e nor adre ne rgic, hist amine rgic an d cho linergic recept or s, whil e no t th ou ght to be respo ns ible for any t he rapeutic act ions of clozapine, are respon sible for many of t he d r ugs side effec ts .
C loza pi ne, un like typi cal a n t ipsycho t ics, binds pr eferenti all y to OA recept or s in th e mesocor t ica l and mesolimbic regions of th e bra in (i6) . In addit ion, clozapine has a rel atively g rea ter affinity fo r th e 0 1 re ce ptor com pa re d wit h t he O 2 re ceptor (26) .
These prope rti es may expla in why clozapine has a very low incide nce of EPS. Farde e t a l (1992) demon strat ed with positron e m iss ion tomography th at O 2 receptor occupancy in th e basal gang lia of pati ents t reat ed with clozap ine was 38% to 63%, sig nifica nt ly lower t ha n th e 70% to 89% th a t was found in pa tients on typ ical a nt ipsyc ho t ics, indicating less nig ro striat al blockad e in pa ti e nt s on clozapin e (27) . Furthe r evid ence su pport ing th e re la t ive se lect ivity of clozapine for dis cret e dop a mi ne rgic pat hways is th at its effects o n th e t ube ro infundi bul a r sys te m is minim al a nd transie nt. Th is is based on evidence t hat plasma prola ctin conce nt ra t io ns are not eleva te d in pa t ien ts on clozapine t herapy, exce pt for an initi a l marginal incr ease th at is occasionally observed whi ch ra pid ly re t urns to bas e line with con t inue d treatm en t (28, 29) . This is in con t rast to typi cal a n t ipsyc hot ics, whi ch elevat e plasma prolactin conce n t ra t ions throughout th erapy (30 ) .
Pharmacokinetics
The bio avail ability of cloza pinc varies markedl y a mo ng published repor ts, bu t ave rages 50 to 60 percent of the oral do se, a nd mo st of th e d ru g is pro t ein bound (21) . Peak plasma co nce n t ra tions are a ttaine d ab out 2 hours afte r inges tion, a nd side effec ts, especia Ily orthostatic hypot ension, typi call y peak a t t his t im e (21). T he m et abolism of cloza pine is co m plex, as it unde rgo es multipl e ox idation reactions a nd d e m ethylation in th e liver, resulting in 80% of th e dru g being exc reted as metabolit es (31 ,32) . Th e half-life e lim ina tion of cloza pine is 12 to 16 ho urs, whi ch allows for co nve nie n t twic e-a-d ay dosing. Pl asm a drug level s in t he range of 200 to 400 ng /ml are co m mo n in patients on a typical do se of 300 to 500 mg /day (2 1). In it iall y, plasma drug conce n t ra t ions did not seem to corre la te we Il with dru g response; however, more recent d ata indicat es that th e maj orit y of patien ts wh o res po nd to cloza pine have drug level s of 350 ng /ml or g reate r (Me ltze r, unpublish ed d at a ). Furth ermore, nonrespond ers with blood levels bel ow 350 ng /ml have conve r te d to responders by incr easing th e dos e of cloza pine to achi eve this minimu m plasm a con centration . Th erefore, in at least a subpopulation of pati ents, plasm a d rug co ncentrations co rre la te weIl with clini cal response to c1ozapine.
Clinical Response
There have been num erous co nt ro lle d trial s com paring th e efficacy of typical antipsychotics with c1ozapine. Shopsin e t a l (197 9) cond uc te d a d ouble-blind comparison of cloza pine a nd chlo rpro m az ine in th e t reatm ent of ac u te ly psych ot ic sch izophrenic patients and found cloza pine was eq ua l or superior to chlorpromazine in co nt roIling psychotic sym ptom s (19) .
H owever, it was th e hallmark , multicent er st udy by Kan e e t a l (1988) that clearly est a blishe d the efficacy of cloza pine in treatm ent-resist an t sch izo phr enic patients (20) . This study included pati ents who m et DSM-III cr iteria for schizo ph renia a nd who had pr eviously fail ed to respond to a t least 3 different typica l ant ipsychotic drugs . Pati ents initially underwent a prosp ective, sing le-blind tria l of ha lope ridol (m ean dosage 6 1 mg/day) for six week s. Ei ghty percent (268) of th e pat ie n ts fai led to respond, a nd were randomized in a doubl e-blind manne r to treatm en t wit h e it he r cloza pine (up to 900 mg/day) or chlor pro mazine (up to 1800 mg /day). After six weeks, 30% of patients in th e c1ozapine-treat ed g ro up were classi fied as respond ers co m pa re d with 4% in th e chlor pro mazine -t reate d gro up. It was a lso no ted th at negative, as well as positive, symptom s improved in pati ents who rece ived c1ozapin e.
In a recent study by Pickar e t al (1992) , 21 patients with schizoph renia who were e it he r treatm ent-resistant or unable to tol erat e typi cal a n t ipsyc ho tic medicat ions were en ro lled in a cro ssove r , pla cebo-controlled , double-blind co m pa rison tria l of cloza pine a nd fluphen azin e (33) . Thirty-eight percent (n = 8) of th e pa tie n ts demon-strated greater improvem ent with c1ozapine, and cloza pine sig nifica nt ly red uced bot h pos it ive a nd negat ive symptoms com pa re d with fluph enazin e and placebo. No improvem ent in negative symptoms wa s obs erved with fluph ena zin e trea t m e n t or pla cebo. It was al so found that low ratios of ce re bros pina l fluid homova nill ic acid (a me tabolite of DA) to 5-hydroxyindoleacet ic ac id (a m etabolite of se ro to nin) pr ed icted cloza pine superiority, suggesting that a n imbalan ce. between t hese two syst ems m ay be responsibl e for producin g som e sympt oms of sc hizo phrenia, a nd that th e dual act ion of cloza p ine on both DA and 5-HT syst em s co r rec ts thi s imbal an ce. In addit ion, pa t ie nts who experienced significant EPS with fluph enazin e treat m ent had a more favorable respon se to c1ozapine.
Clinical Use
C lozapin e is curre nt ly ava ila ble as sco re d 25 m g a nd un sco red 100 mg table ts. Pa t ie n ts are typi ca lly s ta r t ed on 25 mg twice-daily, but elde rly pati ents may need to begin with 12.5 m g dail y. The dos e is titrat ed upward by 25 to 50 mg every day (or in 12.5 mg incr em ents in th e e lde rly) as tolerat ed. Rapid up wa rd ti tra ti on ma y be limit ed by adverse effec ts, mo st not abl y orthostatic hypot ension a nd seda tion. If pat ients are in itiat ed o n cloza pine th erapy on an outpatient basis, less aggressive titration is recommend ed sin ce patients ca nno t be closely mon it ored . Although th ere is a wid e range of report ed effec t ive d a ily dos es (fro m 25 to 900 mg), a dose of 300 to 500 mg per day has been shown to be th e effec t ive do se range for th e maj ori ty of schizoph renic patients (21) .
What const it u te s an ad equ at e trial of cloza pine is st ill being det ermined , bu t it is clear that many pat ients may not show any significant improvem ent unt il 3 to 6 mont hs in to th erapy (M eltze r , unpublish ed data) . Furthermore, many pa tien ts demonstrat e con t inua l improvem ent afte r 6 to 12 m onths of cloza pine t reat men t (6). This se ems to-be a uniqu e feature of c1ozapine, and e m phas izes th e import an ce of a lo ng-te r m t ri a l before the drug is discontinu ed in a patient du e to pr esum ed Jack of efficacy .
Clozapine treatm ent should not be initi at ed in patients with a his to ry of a myeloproliferat ive disord er, previous c1ozapine-induced g ra n ulocytope nia or agranulocyt osis, or a WB C of less than 3500 /mm 3 . A rela tive con t ra indica tion to trea t m en t with cloza pine includes con current use of other m edi cations with th e pot e n tial for bone marrow su ppression (ie. carbamazepine) . Additionall y, th e coad m inist ra t ion of clozapinc wit h be nzo diazepines should be do ne with ca u tion because of seve ral reports of sudden d eath in patients on cloza pine who have al so received a benzod ia zepine (34 ,35) . At this time, how ever, th ere is no ab solute con t ra ind icat ion to th e conc urre nt us e of benzod iaz ep ines with c1ozapine.
Adverse Efficts
Agra nulocy tos is is t he primary conce rn with th e us e of c1ozapine; a nd th e ex tent to whi ch patients are monitored highlights th e con cern ove r this ge ne ra lly reve rsible but pot entiall y fatal adve rse eve n t (21 ,36) . W eekl y WB C s are mandatory in a ll patients o n c1ozapine, whi ch all ows for th e ea rly d et ecti on ofle u kop enia or g ra nulocytop eni a, sho uld it occ u r. However, it sho uld be not ed th a t fluc tuat ions in whit e blood cou n ts a re co m mo n in patients on c1ozapine, but a ny downw a rd trend in co unts should be clos ely sc ru t inized . Th e incid en ce of agranulocyt osis is a bou t 0.6 percent, a nd leukopeni a 1.8 percent (21) . Th e mech anism of ag ra nulocytosis is unk nown a nd it do es not a ppe a r to be dos e-relat ed. The va st maj ority of cases have occured within th e first 6 months of th erap y, but th ere have been isolat ed re port s of agranulocyt osis occuring in patients a fte r 15 months of treatm ent. Recove ry gene ra lly occurs within three week s following discontinuation of cloza pine (22) .
Clozapine, lik e typi cal antipsychotic dru gs , lowers th e se izu re t hres hold and ma y pr ecipit at e se izu res . U nlike ag ra nu locytos is, this is clearly a dos e-relat ed ph enome no n, with th e incid en ce ran gin g fr om 0.6 percent in pa ti e nts on less than 300 mg per day, to 14 percent in patients taking ove r 600 mg per day (22) . In addition to th e a bso lu te do se of c1ozapin e, th e rat e of titration is a lso a m aj or factor affecting th e incid en ce of seizures. 111 patients a t high risk or wh o a re on m or e th an 600 mg of cloza pine a da y, prophl axis with a n a nt ico nvulsa n t, suc h as va lproic acid , shou ld be co ns ide re d . If a se izu re does occ u r, th e me d ica t ion may be reinstitut ed at hal f th e pr eviou s dose a fter a n a n t ico nvulsa n t is a dde d .
There are num erou s other adverse effec ts du e to th e an tagonis tic properties of cloza pine a t histaminergic, noradren ergic and choline rg ic recept ors. Th e incide nce of th ese effec ts varies a mo ng publish ed rep orts, but th ey include : seda t ion, ta chycardi a , o rt hos tat ic hyp ot en sion , cons t ipa t ion, di zzin ess, sia lo r r hea (pa radox ica l, co ns ide ring cloza pine is a pot ent mu scarinic a n tagonist), hyperth e r mi a and weigh t ga in, among o t he rs. While th ese side effec ts m ay be bothersom e, th ey rarely necessita te stopping th e m edi cation, gen erally improve with con tinue d treatm ent , ca n sometim es be m anaged with adj u nc t ive m edi cation s, a nd m ay be mini mi zed wi th slow titration of th e dru g.
CONC LUSION
Th e treatm ent of schizo phre nia has been g rea t ly e nhanced by th e recent ex plosion of resea rc h in neu ro scien ce . Th e beli ef th at schizophrenia is purely a n illn ess of DA hyp eract ivit y is no longe r u nive rsally acce p ted . C learly som e sym pto ms m ay be expla ine d by DA hyperacti vit y, but ot he rs a ppear to be secondary to hypoactive DA circ uits . Thus, th e beli ef that D 2 blo ckade is th e most import a n t factor in th e treatm e nt of schizo phre nia is a lso losin g wid esp read support. Althou gh D 2 blockad e st ill se ems to play a m aj or ro le in th e t reat m e n t ofposit ive symptoms, t he re is sufficie n t dat a to suppo rt a role for D 1 re ceptor bloc kad e as we ll. T he conce pt of negative sym p to ms and th e succ ess of drugs th at are 5-HT 2 a ntagonists in th e treatm ent of th ese sym p toms is th e st ro nges t evide nce to dat e suppo rting a putative neurotran smitt er abno r mality ot her th an DA in sch izo phrenia. Furth ermore, th e co nce p t of " ne u ro t ra ns m itter ba la nce ," which emp has izes th e int e ract io n be tween different neu rotran sm itt e r sys tems, as bei ng im port an t for normal br ain fun cti on a nd a lte re d in patients with sc hizop hre nia is ga ining wid espread acceptance among lead ing res earch ers in th e field . Thus, lik e clozapin e, newer med icat ion s for the treatm ent of schizophrenia will not be pure D 2 a nt agonists. T o th e co nt rary, newe r a n t ipsycho t ics will have less D 2 blockad e, more D 1 a nd 5-HT 2 blockad e, an d hopefull y less adren ergic, cho line rg ic, a nd histamin ergic blockad e.
In review, num erous nondopamin ergic sys te ms have been im plica ted in th e pa th ophysiology of schizophrenia, including those that uti lize th e neurotran smi tt ers serotonin, rr-opio id. : neurot en sin, a nd N-m ethyl-D-asp art at e. Th is has led to t he devel opment of a new ge ne ra t io n ofdrugs for th e treatm ent of t his major psychia t ric illn ess. Clozapine is th e first a ty pica l a ntipsyc ho t ic th at has proven to be effective in schizoph reni a, eve n in those patients wh o are othe rwise treatm ent-r esist an t to typi ca l a nt ipsycho tic drugs. Furthermore, clozapin e improves nega tive, as well as positive, sym pto ms of sc hizo phre nia, a nd has littl e pot enti al for inducing movement disorders.
